BioVaxys Technology Corp. develops immunotherapy and vaccine programs based on its DPX antigen delivery and immune-educating technology platform. The clinical-stage biotechnology company reports developments across oncology, infectious disease, allergy, and other immune-disease applications, with recurring updates on DPX-formulated products such as maveropepimut-S, or MVP-S, and DPX-SurMAGE.
BioVaxys news commonly covers clinical-study results in cancer indications including ovarian, bladder, and breast cancer; licensing activity tied to DPX technology; SpayVac-related immunocontraceptive vaccine developments through a licensee; integration of former IMV assets; and capital-structure actions such as share consolidation, financing activity, warrants, and asset-purchase agreement amendments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.